Intra-Cellular Therapies Inc.
ITCI
ITCI was delisted on the 1st of April, 2025.
139 hedge funds and large institutions have $1.19B invested in Intra-Cellular Therapies Inc. in 2016 Q2 according to their latest regulatory filings, with 29 funds opening new positions, 58 increasing their positions, 28 reducing their positions, and 16 closing their positions.
200% more funds holding in top 10
Funds holding in top 10: 1 → 3 (+2)
107% more repeat investments, than reductions
Existing positions increased: 58 | Existing positions reduced: 28
81% more first-time investments, than exits
New positions opened: 29 | Existing positions closed: 16
56% more call options, than puts
Call options by funds: $22.7M | Put options by funds: $14.6M
46% more capital invested
Capital invested by funds: $812M → $1.19B (+$374M)
9% more funds holding
Funds holding: 127 → 139 (+12)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$28.1M |
| 2 |
BB
BB Biotech
Schaffhausen,
Switzerland
|
+$25.2M |
| 3 |
O
OrbiMed
New York
|
+$21.3M |
| 4 |
EC
EcoR1 Capital
San Francisco,
California
|
+$8.8M |
| 5 |
Norges Bank
Oslo,
Norway
|
+$7.08M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VAM
Visium Asset Management
New York
|
-$31.4M |
| 2 |
Millennium Management
New York
|
-$22.1M |
| 3 |
EAM
EverPoint Asset Management
Stamford,
Connecticut
|
-$12.6M |
| 4 |
SAM
Senzar Asset Management
New York
|
-$8.56M |
| 5 |
Renaissance Technologies
New York
|
-$6.5M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
LCM
151
Laurion Capital Management
New York
| – | -$206K | -7,400 | Closed |
|
152
SG Americas Securities
New York
| – | -$116K | -4,188 | Closed |
|
|
MAM
153
Meeder Asset Management
Dublin,
Ohio
| – | -$99K | -3,574 | Closed |
|
|
PAM
154
Paradigm Asset Management
New York
| – | -$55.6K | -2,000 | Closed |
|
155
Simplex Trading
Chicago,
Illinois
| – | -$67.1K | -1,867 | Closed |
|
ITCI Hedge Fund Activity: Q2 2016 in Review
139 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Intra-Cellular Therapies Inc. (ITCI) for Q2 2016, worth a combined $1.19B — up 46% from $812M a quarter earlier.
Buyers outnumbered sellers: 29 funds opened new ITCI positions and 16 closed out — a net gain of 13 holders — while 58 added to existing stakes and 28 trimmed.
The largest buyer was Vanguard Group, adding an estimated $28.1M. The largest seller was Visium Asset Management, cutting an estimated $31.4M.
- 139 institutional investors held Intra-Cellular Therapies Inc. (ITCI) as of Q2 2016, up from 127 in Q1 2016.
- Funds reported $1.19B of Intra-Cellular Therapies Inc. stock for Q2 2016, up 46% quarter-over-quarter.
- 29 funds opened new Intra-Cellular Therapies Inc. positions in Q2 2016 and 16 closed out, a net change of +13 holders.
- The largest Intra-Cellular Therapies Inc. buyer in Q2 2016 was Vanguard Group, an estimated $28.1M added.
- The largest Intra-Cellular Therapies Inc. seller in Q2 2016 was Visium Asset Management, an estimated $31.4M sold.
Based on aggregated 13F filings for Q2 2016.